Étiqueté : JAMA

Figure 3. Common Adverse Reactions and Grades Within 7 Days After 2 Doses in the Safety Analysis Set © DR

27/05/2021

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

This prespecified interim analysis of a randomized clinical trial included 40 382 participants who received at least 1 dose of a 2-dose inactivated vaccine series developed from either SARS-CoV-2 WIV04 (5 µg/dose) or HB02 (4 µg/dose) strains or an aluminum hydroxide–only control, with a primary end point of the incidence of symptomatic COVID-19 at least 14 days after the second injection. The efficacy for the 2 vaccines, compared with an aluminum hydroxide–only control, was 72.8% in the WIV04 group and 78.1% in the HB02 group; both comparisons were statistically significant.

Presse / Ressources Académiques

14/08/2020

[Chine] China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal

BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.

Presse / Ressources Académiques

14/05/2020

[Japon] Corrélation entre l’inoculation du vaccin BCG et le volume de décès liés au covid-19

Selon une étude de Dr. Miyasaka (宮坂昌之), une corrélation peut être constatée entre l’inoculation du vaccin BCG (bilié de Calmette et Guérin) contre certaines souches de tuberculose et le volume de décès liés au covid-19, dans un rapport de 1 à 1800, sans que le vaccin n’empêche cependant les contaminations.

Le Dr Cheng Hao-yuan [鄭皓元] (à d.) du CDC de Taiwan a présenté le 2 mai lors de la conférence de presse du Quartier général de lutte épidémique (CECC) l’étude publiée la veille dans JAMA Internal Medicine. © CNA

Presse / Ressources Académiques

05/05/2020

Une étude taiwanaise sur la transmission du Covid-19 publiée dans la revue JAMA Internal Medicine

Une étude menée sur les 100 premiers cas confirmés de Covid-19 à Taiwan ainsi que sur leurs contacts proches a été publiée le 1er mai dans le prestigieux Journal of the American Medical Association (JAMA) Internal Medicine. Elle confirme que le risque de transmission du coronavirus à ses proches est le plus élevé pendant les cinq jours suivant l’apparition des symptômes, mais aussi avant même leur apparition.

Ressources Académiques

14/04/2020

Response to COVID-19 in Taiwan. Big Data Analytics, New Technology, and Proactive Testing

Taiwan is 81 miles off the coast of mainland China and was expected to have the second highest number of cases of coronavirus disease 2019 (COVID-19) due to its proximity to and number of flights between China. The country has 23 million citizens of which 850 000 reside in and 404 000 work in China. In 2019, 2.71 million visitors from the mainland traveled to Taiwan. As such, Taiwan has been on constant alert and ready to act on epidemics arising from China ever since the severe acute respiratory syndrome (SARS) epidemic in 2003. Given the continual spread of COVID-19 around the world, understanding the action items that were implemented quickly in Taiwan and assessing the effectiveness of these actions in preventing a large-scale epidemic may be instructive for other countries.